Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LY2780301 |
Synonyms | |
Therapy Description |
LY2780301 is an inhibitor of AKT and P70S6 kinases, which prevents signaling of the PI3K/AKT pathway thereby possibly resulting in antitumor activity (PMID: 25902900, PMID: 28877935). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LY2780301 | LY 2780301|LY-2780301 | Akt Inhibitor (Pan) 21 S6 Kinase Inhibitor 5 | LY2780301 is an inhibitor of AKT and P70S6 kinases, which prevents signaling of the PI3K/AKT pathway thereby possibly resulting in antitumor activity (PMID: 25902900, PMID: 28877935). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA E545K | colon cancer | predicted - sensitive | LY2780301 | Case Reports/Case Series | Actionable | In a Phase I trial, a colon cancer patient harboring PIK3CA E545K was sensitive to LY2780301, demonstrating stable disease for approximately 125 days (PMID: 25902900). | 25902900 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|